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Myeloablative allogeneic stem cell transplant (MA AlloSCT)
for childhood AML may be associated with signiﬁcant acute
toxicity, late effects and/or recurrent disease (Woods et al;
Blood, 2001). Reduced intensity (RI) AlloSCT may offer less
acute toxicity and/or reduced late effects for children with
cancer (Del Toro/Cairo et al; BMT, 2004, Satwani/Cairo,
BBMT, 2005). Gemtuzumab ozogamicin (GO) has induced re-
sponses in 30% of patients with recurrent CD33 AML (Siev-
ers et al; J Clin Oncol, 2001). We explored the feasibility and
toxicity of RI AlloSCT followed by GO targeted immunother-
apy as consolidation in children with CD33 AML. Eleven
patients, 11 years (0.5-21) with CD33 AML, 8-CR1 and
3-CR2 (M0-1, M1-1, M3-1, M4-3, M4/5-1 and M5-4) received
ﬂudarabine 30mg/m2x6d and busulfan 3.2-4mg/kgx2d 	 rabbit
ATG 2mg/kgx4d. Donors: 7 6/6 HLA related peripheral blood
stem cells (RPBSC), 1 5/6 RPBSC, 1 6/6 related cord blood
(CB) and 2 4/6 unrelated CB. GOx2 was administered 60d
post AlloSCTx2 (8wks apart), following a dose escalation design
(4.5, 6 and 7.5mg/m2). Median neutrophil and platelet engraft-
ment after RI AlloSCT for 10/11 evaluable patients was on
d15	4 and d16	16, respectively. One primary graft failure
relapsed after a MA AlloSCT. Donor chimerism in 10/11 evalu-
able patients was 97	2% (d30) and 95	11% (d365). Eight
patients received two doses of GO (4.5mg/m2 [n3], 6mg/m2
[n4], 7.5mg/m2 [n1]); one patient received one dose of GO
and relapsed and died of AML. One patient has not yet reached
d60. The median time between AlloSCT and 1st and 2nd doses
of GO was 70 and 150 d, respectively. All patients experienced
grade 4 neutropenia following each GO course with recovery
(ANC500/mm3x2d) on median d18 and 14, respectively.
Grade 4 thrombocytopenia was only observed in 6/17 GO
courses, with recovery (platelets20,000/mm3, without transfu-
sion) following each GO course on median d4 and 0, respec-
tively. Eight patients are alive with no evidence of disease
(NED); the ninth, with NED expired from cGVHD. Estimated
1-yr OS for CR1 and CR2 is 67.5%. No patients have developed
dose-limiting toxicity secondary to GO. RI AlloSCT in average
risk AML results in 95% donor chimerism and administration
of GO post RI AlloSCT is well tolerated. The maximal tolerated
dose has yet to be determined for GO post RI AlloSCT in
children with CD33 AML.
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NON-INVASIVE PET IMAGING OF T CELLS DERIVED FROM UMBILICAL
CORD BLOOD
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Genetic introduction of chimeric antigen receptors (CARs) re-
directs the speciﬁcity of T cells for tumor antigens such as CD19
on B-lineage malignancies. Adoptive transfer of donor-derived
CD19-speciﬁc CART cells may be used to augment graft-versus-
leukemia/lymphoma (GVL)-effect after allogeneic hematopoietic
stem-cell transplantation in general, and umbilical cord blood
transplantation in particular. To help assess the therapeutic poten-
tial of this adoptive immunotherapy we have generated the genetic
tools to non-invasively image CAR T cells in vivo. A four-func-
tion reporter transgene has been developed for co-expression with
a CAR to achieve (i) in vitro selection of CAR T cells in cytocidal
concentrations of hygromycin B, (ii) in vivo ganciclovir-dependent
conditional ablation and (iii) in vivo simultaneous bioluminescence
imaging (BLI) with (iv) in vivo positron emission tomography
(PET). For imaging, the plasmid expressing the 2nd-generation
CD19-speciﬁc CAR (CD19RCD28) was modiﬁed to encode the
reporter gene ffLucHyTK, which fuses Fireﬂy Luciferase (ffLuc),
hygromycin (Hy) phosphotransferase and HSV1-derived thymi-
dine kinase (TK). We show that CD19-speciﬁc T cells expressing
the HyTK- fusion transgene take up PET-tracer in vitro and can
be tracked in vivo in mice by BLI and microPET imaging after
intravenous injection of d-luciferin and [18F]FEAU, respectively.
This is among the ﬁrst reports demonstrating that HyTK fusion
gene can be used not only for selection and suicide, but also for
PET. Since the HyTK transgene is currently used in clinical trials,
and co-expression of a TK suicide gene may be necessary to ensure
safety of initial protocols infusing T cells expressing second-gen-
eration CARs (which can activate T cells through chimeric CD3-
and CD28), this report should encourage investigators to under-
take PET imaging of adoptively transferred HyTK cells. The
imaging modalities used in this project can be readily translated,
and we expect that the clinical application of T-cell-PET will help
physicians and their patients dissect the beneﬁts of allogeneic
adoptive immunotherapy of CAR T cells with respect to toxicity
(e.g., graft-versus-host-disease) and efﬁcacy (GVL). Indeed, devel-
oping methodologies that are capable of generating quantitative,
non-invasive, longitudinal, and spatial in vivo information about
the dynamic process of infused T cells will be critical to our general
understanding of adoptive immunotherapy in humans.
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HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN CHILDREN WITH
ACUTE LYMPHOCYTIC LEUKEMIA (ALL) IN SECOND COMPLETE REMIS-
SION (CR2): SIMILAR RESULTS WITH GRAFTS FROM UNRELATED DO-
NORS (URD) AND HLA MATCHED SIBLING DONORS (MSD)
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Background: Transplant decisions for pediatric patients with
ALL in CR2 are often based on timing of relapse and donor
availability. If a MSD is available, HCT will proceed. If not, care
may be continued with chemotherapy. The role of URD HCT for
these patients is less well established. As advances in supportive
care measures have resulted in less treatment related mortality
(TRM) and improved survival after URD HCT, the approach to
treating such patients should be reevaluated.
Materials and Methods: Between 1990-2004, 85 children with
ALL in CR2 underwent allogeneic HCT at the University of
Minnesota. The median age at HSCT was 7.3 (range 0.9-17.9)
years. Median length of CR1 was 2.1 (range 0.1-6.1) years. Donor
source included 33 MSD bone marrow (BM), 19 HLA-matched
(M) URD BM, 15 HLA-mismatched (MM) URD BM and 16
URD umbilical cord blood (UCB), all but one being MM at 1-2
HLA antigens. All patients received conditioning with cyclophos-
phamide and total body irradiation (/- etoposide in 28 or ﬂu-
darabine in 4). Patients were followed for a median of 6 (range
1.1-13.5) years.
Results: Neutrophil recovery was similar in all 3 groups: 94% in
MSD, 88% in MURD BM, 78% in MM-URD BM and 94% in
UCB (p .43). Overall TRM at one year was signiﬁcantly higher
in MMURD (73%) compared to MSD, MURD and UCB recip-
ients (12%, 21% and 28%, respectively). The incidence of grade
II-IV acute GvHD was higher HCT using of MURD BM
(RR3.2, p.02) and MMURD (RR 7.4, p.01) than MSD BM
or UBC recipients. Similarly, the risk of chronic GvHD was higher
after transplantation of MURD BM (RR 5.4, p.04) and
MMURD BM (RR 8.8, p.03). Relapse rates at 5 years were 37%
for MSD, 16% for MURD BM, 7% for MMURD BM and 33%
for UCB (p.43). Factors associated with a lower risk of relapse
included receiving MMURD BM (RR 6.1, p.01), CR1 1 year
(RR 0.5, p.05) and developing grade II-IV acute GvHD (RR 0.3,
p.01). Probability of 1 year survival after HCT for MSD,
MURD, MMURD and UCB were 70%, 68%, 20%, and 61%
(p.01), respectively. Factors affecting survival included donor
type, length of CR1, presence of T-cell ALL and acute GvHD
(Table). Survival and leukemia free survival after HLA matched
URD BM and HLA mismatched UCB appear to be similar to that
observed after HLA matched BM from sibling donors. Therefore,
parameters used for recommending URD HCT (either HLA
matched URD BM or HLA mismatched UCB) should be similar
to those used for recommending HLA MSD BM for children with
ALL in CR2.
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